Mercy Medical Center - Mcauley Plaza
Welcome,         Profile    Billing    Logout  
 5 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Thuluvath, Paul J
NCT04588077 / 2020-001766-11: Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

Recruiting
4
200
US
Heplisav-B Injectable Product, 2-dose regimen, 2-dose regimen, Heplisav-B Injectable Product, 3-dose regimen, 3-dose regimen
Mercy Medical Center
Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease
07/24
07/24
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
ARGON-2, NCT04378010: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Terminated
2b
98
Europe, Canada, US, RoW
EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo
Enanta Pharmaceuticals, Inc
Non-Alcoholic Steatohepatitis
10/21
11/21
FRESH, NCT05639543: FXR Effect on Severe Alcohol-Associated Hepatitis () Study

Recruiting
2
50
Europe, US
INT-787, Placebo
Intercept Pharmaceuticals
Alcohol Associated Hepatitis
12/24
12/24
NCT05239468: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Active, not recruiting
2
60
US
Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo
Intercept Pharmaceuticals
Primary Biliary Cholangitis
11/24
02/25
LIVER-1, NCT05199259: Multi-analyte Blood Test Clinical Trial

Recruiting
N/A
1200
US
Multi-analyte Blood Test
Helio Genomics
Liver Cirrhosis, Liver Cancer, HCC, Hepatocellular Carcinoma
01/25
03/25
TARGET-HCC, NCT02954094: A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

Recruiting
N/A
10000
Europe, US
Target PharmaSolutions, Inc.
Hepatocellular Cancer
10/24
10/24
NCT03692897: An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

Recruiting
N/A
5000
Canada, US
All approved therapies for the treatment of Chronic Hepatitis B (CHB)
Target PharmaSolutions, Inc.
Hepatitis B, Hepatitis, Liver Diseases
01/26
01/26
Dotherow, Pierce
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26

Download Options